Key result
Glycated albumin provides a reliable alternative to HbA1c for glycemic monitoring in stable T2DM.
Why the study?
Does glycated albumin (GA) provide a more reliable assessment of glycemic control compared to HbA1c in stable T2DM patients?
Cohort
Does glycated albumin (GA) provide a more reliable assessment of glycemic control compared to HbA1c in stable T2DM patients?
Answers are grounded in this paper and cite their sources.
Glycated albumin may serve as a reliable adjunct or alternative to HbA1c for glycemic monitoring in stable T2DM patients, particularly when erythrocyte lifespan variations render HbA1c inaccurate.
BACKGROUND: Glycemic control is essential in managing type 2 diabetes mellitus (T2DM) to reduce the risk of complications, including diabetic nephropathy. Traditionally, glycated hemoglobin (HbA1c) has been the gold standard for assessing long-term glycemic control. However, glycated albumin (GA) has emerged as a potential alternative due to its shorter lifespan and reduced sensitivity to erythrocyte lifespan changes. AIMS AND OBJECTIVES: This study aimed to compare the efficacy of GA and HbA1c in evaluating glycemic control in stable T2DM patients, particularly regarding its implications for diabetic nephropathy and associated complications. METHODOLOGY: A comparative analysis was conducted between GA and HbA1c levels in a cohort of stable T2DM patients. The primary focus was on assessing the reliability and clinical applicability of GA as a marker for glycemic control, especially in cases where HbA1c might provide misleading results. RESULTS: The study findings indicated that GA could offer a valuable alternative for glycemic monitoring, especially in clinical scenarios where HbA1c might not accurately reflect glycemic status due to erythrocyte lifespan variations. The use of GA could enhance the precision of glycemic control assessment, thus potentially improving patient care. CONCLUSION: The results underscore the importance of incorporating GA in clinical practice as an adjunct to HbA1c, particularly in situations where HbA1c may be unreliable. GA provides a promising alternative for better management of glycemic control in T2DM patients, potentially impacting the management and progression of diabetic nephropathy.
No takes yet. Share an insight, caveat, or question.
Meher et al. (2024) conducted a cohort in Type 2 diabetes mellitus. Glycated albumin (GA) vs. Glycated hemoglobin (HbA1c) was evaluated on Reliability and clinical applicability of GA as a marker for glycemic control. Glycated albumin (GA) emerged as a valuable alternative to HbA1c for glycemic monitoring in stable T2DM patients, especially when HbA1c may be unreliable due to erythrocyte lifespan variations.
Synapse has enriched 10 related papers. Consider them for comparative context: